-
1
-
-
80054719494
-
American Society of Clinical Oncology 2011 CNS tumors update
-
21999122 10.1586/era.11.151
-
Ahluwalia MS (2011) American Society of Clinical Oncology 2011 CNS tumors update. Expert Rev Anticancer Ther 11:1495-1497
-
(2011)
Expert Rev Anticancer Ther
, vol.11
, pp. 1495-1497
-
-
Ahluwalia, M.S.1
-
2
-
-
84862016653
-
Glioblastoma multiforme imaging: The role of nuclear medicine
-
22642425 1:CAS:528:DC%2BC38Xhs1ykt7%2FL 10.2174/1874471011205040308
-
Alexiou GA, Tsiouris S, Voulgaris S, Kyritsis AP, Fotopoulos AD (2012) Glioblastoma multiforme imaging: the role of nuclear medicine. Curr Radiopharm 5:308-313
-
(2012)
Curr Radiopharm
, vol.5
, pp. 308-313
-
-
Alexiou, G.A.1
Tsiouris, S.2
Voulgaris, S.3
Kyritsis, A.P.4
Fotopoulos, A.D.5
-
3
-
-
44649095050
-
Time course of imaging changes of GBM during extended bevacizumab treatment
-
18389177 10.1007/s11060-008-9573-x
-
Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88:339-347
-
(2008)
J Neurooncol
, vol.88
, pp. 339-347
-
-
Ananthnarayan, S.1
Bahng, J.2
Roring, J.3
Nghiemphu, P.4
Lai, A.5
Cloughesy, T.6
Pope, W.B.7
-
4
-
-
56749156414
-
Analysis of the IDH1 codon 132 mutation in brain tumors
-
18985363 1:CAS:528:DC%2BD1cXhtlyhsbfN 10.1007/s00401-008-0455-2
-
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602
-
(2008)
Acta Neuropathol
, vol.116
, pp. 597-602
-
-
Balss, J.1
Meyer, J.2
Mueller, W.3
Korshunov, A.4
Hartmann, C.5
Von Deimling, A.6
-
5
-
-
52649172327
-
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma
-
18716556 1:CAS:528:DC%2BD1cXhtFKisb3P 10.1097/NEN.0b013e3181845622
-
Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG (2008) Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 67:878-887
-
(2008)
J Neuropathol Exp Neurol
, vol.67
, pp. 878-887
-
-
Bar, E.E.1
Lin, A.2
Tihan, T.3
Burger, P.C.4
Eberhart, C.G.5
-
6
-
-
77954720781
-
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
-
20458050 1:CAS:528:DC%2BC3cXptFKmu78%3D 10.1200/JCO.2009.26.3988
-
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823
-
(2010)
J Clin Oncol
, vol.28
, pp. 2817-2823
-
-
Batchelor, T.T.1
Duda, D.G.2
Di Tomaso, E.3
Ancukiewicz, M.4
Plotkin, S.R.5
Gerstner, E.6
Eichler, A.F.7
Drappatz, J.8
Hochberg, F.H.9
Benner, T.10
Louis, D.N.11
Cohen, K.S.12
Chea, H.13
Exarhopoulos, A.14
Loeffler, J.S.15
Moses, M.A.16
Ivy, P.17
Sorensen, A.G.18
Wen, P.Y.19
Jain, R.K.20
more..
-
7
-
-
33846149645
-
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
-
17222792 1:CAS:528:DC%2BD2sXhtFClsLc%3D 10.1016/j.ccr.2006.11.021
-
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95
-
(2007)
Cancer Cell
, vol.11
, pp. 83-95
-
-
Batchelor, T.T.1
Sorensen, A.G.2
Di Tomaso, E.3
Zhang, W.T.4
Duda, D.G.5
Cohen, K.S.6
Kozak, K.R.7
Cahill, D.P.8
Chen, P.J.9
Zhu, M.10
Ancukiewicz, M.11
Mrugala, M.M.12
Plotkin, S.13
Drappatz, J.14
Louis, D.N.15
Ivy, P.16
Scadden, D.T.17
Benner, T.18
Loeffler, J.S.19
Wen, P.Y.20
Jain, R.K.21
more..
-
8
-
-
34249332411
-
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
-
17483311 1:CAS:528:DC%2BD2sXltVyku74%3D 10.1158/0008-5472.CAN-06-4180
-
Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010-4015
-
(2007)
Cancer Res
, vol.67
, pp. 4010-4015
-
-
Beier, D.1
Hau, P.2
Proescholdt, M.3
Lohmeier, A.4
Wischhusen, J.5
Oefner, P.J.6
Aigner, L.7
Brawanski, A.8
Bogdahn, U.9
Beier, C.P.10
-
9
-
-
56649097479
-
MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples
-
18936738 1:CAS:528:DC%2BD1cXhtl2qt7nL 10.1038/labinvest.2008.100
-
Bettstetter M, Dechant S, Ruemmele P, Vogel C, Kurz K, Morak M, Keller G, Holinski-Feder E, Hofstaedter F, Dietmaier W (2008) MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples. Lab Invest 88:1367-1375
-
(2008)
Lab Invest
, vol.88
, pp. 1367-1375
-
-
Bettstetter, M.1
Dechant, S.2
Ruemmele, P.3
Vogel, C.4
Kurz, K.5
Morak, M.6
Keller, G.7
Holinski-Feder, E.8
Hofstaedter, F.9
Dietmaier, W.10
-
10
-
-
84255160601
-
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma
-
22190458 1:CAS:528:DC%2BC38Xlsl2nuw%3D%3D 10.1101/gad.176800.111
-
Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, Turski A, Azodi Y, Yang Y, Doucette T, Colman H, Sulman EP, Lang FF, Rao G, Copray S, Vaillant BD, Aldape KD (2011) The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 25:2594-2609
-
(2011)
Genes Dev
, vol.25
, pp. 2594-2609
-
-
Bhat, K.P.1
Salazar, K.L.2
Balasubramaniyan, V.3
Wani, K.4
Heathcock, L.5
Hollingsworth, F.6
James, J.D.7
Gumin, J.8
Diefes, K.L.9
Kim, S.H.10
Turski, A.11
Azodi, Y.12
Yang, Y.13
Doucette, T.14
Colman, H.15
Sulman, E.P.16
Lang, F.F.17
Rao, G.18
Copray, S.19
Vaillant, B.D.20
Aldape, K.D.21
more..
-
11
-
-
85047690508
-
Opinion: The origin of the cancer stem cell: Current controversies and new insights
-
16327766 1:CAS:528:DC%2BD2MXht1Wgu73K 10.1038/nrc1740
-
Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ (2005) Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5:899-904
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 899-904
-
-
Bjerkvig, R.1
Tysnes, B.B.2
Aboody, K.S.3
Najbauer, J.4
Terzis, A.J.5
-
12
-
-
61849117290
-
Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: A dynamic contrast-enhanced MRI study using gadopentate
-
18814988 1:CAS:528:DC%2BD1MXjtFKmur4%3D 10.1016/j.mri.2008.07.021
-
Bradley DP, Tessier JJ, Lacey T, Scott M, Jurgensmeier JM, Odedra R, Mills J, Kilburn L, Wedge SR (2009) Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magn Reson Imaging 27:377-384
-
(2009)
Magn Reson Imaging
, vol.27
, pp. 377-384
-
-
Bradley, D.P.1
Tessier, J.J.2
Lacey, T.3
Scott, M.4
Jurgensmeier, J.M.5
Odedra, R.6
Mills, J.7
Kilburn, L.8
Wedge, S.R.9
-
13
-
-
72449155176
-
EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
-
19945857 1:CAS:528:DC%2BD1MXhs1WgtLfJ 10.1016/j.ejca.2009.10.029
-
Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, Mirimanoff RO, Kros JM, van den Bent MJ (2010) EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 46:348-354
-
(2010)
Eur J Cancer
, vol.46
, pp. 348-354
-
-
Brandes, A.A.1
Stupp, R.2
Hau, P.3
Lacombe, D.4
Gorlia, T.5
Tosoni, A.6
Mirimanoff, R.O.7
Kros, J.M.8
Van Den Bent, M.J.9
-
14
-
-
77957069911
-
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase i study
-
20156802 1:CAS:528:DC%2BC3cXovFCqurc%3D 10.1093/neuonc/nop070
-
Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD (2010) Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol 12:608-613
-
(2010)
Neuro Oncol
, vol.12
, pp. 608-613
-
-
Butowski, N.1
Chang, S.M.2
Lamborn, K.R.3
Polley, M.Y.4
Parvataneni, R.5
Hristova-Kazmierski, M.6
Musib, L.7
Nicol, S.J.8
Thornton, D.E.9
Prados, M.D.10
-
15
-
-
84863011588
-
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
-
21896554 10.1093/neuonc/nor130 1:CAS:528:DC%2BC38Xhtl2hsbrJ
-
Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD (2011) Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol 13:1331-1338
-
(2011)
Neuro Oncol
, vol.13
, pp. 1331-1338
-
-
Butowski, N.1
Chang, S.M.2
Lamborn, K.R.3
Polley, M.Y.4
Pieper, R.5
Costello, J.F.6
Vandenberg, S.7
Parvataneni, R.8
Nicole, A.9
Sneed, P.K.10
Clarke, J.11
Hsieh, E.12
Costa, B.M.13
Reis, R.M.14
Hristova-Kazmierski, M.15
Nicol, S.J.16
Thornton, D.E.17
Prados, M.D.18
-
16
-
-
34247499001
-
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
-
17404084 1:CAS:528:DC%2BD2sXjs12rtrs%3D 10.1158/1078-0432.CCR-06-2149
-
Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13:2038-2045
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2038-2045
-
-
Cahill, D.P.1
Levine, K.K.2
Betensky, R.A.3
Codd, P.J.4
Romany, C.A.5
Reavie, L.B.6
Batchelor, T.T.7
Futreal, P.A.8
Stratton, M.R.9
Curry, W.T.10
Iafrate, A.J.11
Louis, D.N.12
-
17
-
-
33745575716
-
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
-
16782910 1:CAS:528:DC%2BD28XntV2hurg%3D 10.1200/JCO.2005.04.3414
-
Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714
-
(2006)
J Clin Oncol
, vol.24
, pp. 2707-2714
-
-
Cairncross, G.1
Berkey, B.2
Shaw, E.3
Jenkins, R.4
Scheithauer, B.5
Brachman, D.6
Buckner, J.7
Fink, K.8
Souhami, L.9
Laperierre, N.10
Mehta, M.11
Curran, W.12
-
18
-
-
0032494479
-
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
-
9776413 1:STN:280:DyaK1cvkslejug%3D%3D 10.1093/jnci/90.19.1473
-
Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1473-1479
-
-
Cairncross, J.G.1
Ueki, K.2
Zlatescu, M.C.3
Lisle, D.K.4
Finkelstein, D.M.5
Hammond, R.R.6
Silver, J.S.7
Stark, P.C.8
Macdonald, D.R.9
Ino, Y.10
Ramsay, D.A.11
Louis, D.N.12
-
19
-
-
84868214940
-
Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study
-
ASCO MEETING ABSTRACTS (suppl; abstr 2008b)
-
Cairncross JG, Wang M, Shaw EG, Jenkins RB, Scheithauer BW, Brachman D, Buckner JC, Fink KL, Souhami L, Laperriere N, Curran WJ and Mehta MP (2012) Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study. J Clin Oncol 30:ASCO MEETING ABSTRACTS (suppl; abstr 2008b)
-
(2012)
J Clin Oncol
, vol.30
-
-
Cairncross, J.G.1
Wang, M.2
Shaw, E.G.3
Jenkins, R.B.4
Scheithauer, B.W.5
Brachman, D.6
Buckner, J.C.7
Fink, K.L.8
Souhami, L.9
Laperriere, N.10
Curran, W.J.11
Mehta, M.P.12
-
20
-
-
77953023663
-
Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis
-
20044756 10.1007/s00401-009-0632-y
-
Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL (2010) Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 119:509-511
-
(2010)
Acta Neuropathol
, vol.119
, pp. 509-511
-
-
Camelo-Piragua, S.1
Jansen, M.2
Ganguly, A.3
Kim, J.C.4
Louis, D.N.5
Nutt, C.L.6
-
21
-
-
54549108740
-
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
-
Cancer Genome Atlas Research Network 10.1038/nature07385 1:CAS:528:DC%2BD1cXht1yju77J
-
Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068
-
(2008)
Nature
, vol.455
, pp. 1061-1068
-
-
-
22
-
-
75149195336
-
The transcriptional network for mesenchymal transformation of brain tumours
-
20032975 1:CAS:528:DC%2BD1MXhs1SktbzP 10.1038/nature08712
-
Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, Aldape K, Califano A, Iavarone A (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463:318-325
-
(2010)
Nature
, vol.463
, pp. 318-325
-
-
Carro, M.S.1
Lim, W.K.2
Alvarez, M.J.3
Bollo, R.J.4
Zhao, X.5
Snyder, E.Y.6
Sulman, E.P.7
Anne, S.L.8
Doetsch, F.9
Colman, H.10
Lasorella, A.11
Aldape, K.12
Califano, A.13
Iavarone, A.14
-
23
-
-
84860289825
-
A novel treatment for glioblastoma: Integrin inhibition
-
22449214 1:CAS:528:DC%2BC38Xks1OmtLY%3D 10.1586/ern.11.188
-
Chamberlain MC, Cloughsey T, Reardon DA, Wen PY (2012) A novel treatment for glioblastoma: integrin inhibition. Expert Rev Neurother 12:421-435
-
(2012)
Expert Rev Neurother
, vol.12
, pp. 421-435
-
-
Chamberlain, M.C.1
Cloughsey, T.2
Reardon, D.A.3
Wen, P.Y.4
-
24
-
-
21044431575
-
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
-
16012795 1:CAS:528:DC%2BD2MXmtVymtLY%3D 10.1007/s10637-005-1444-0
-
Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357-361
-
(2005)
Invest New Drugs
, vol.23
, pp. 357-361
-
-
Chang, S.M.1
Wen, P.2
Cloughesy, T.3
Greenberg, H.4
Schiff, D.5
Conrad, C.6
Fink, K.7
Robins, H.I.8
De Angelis, L.9
Raizer, J.10
Hess, K.11
Aldape, K.12
Lamborn, K.R.13
Kuhn, J.14
Dancey, J.15
Prados, M.D.16
-
25
-
-
79958210803
-
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
-
21432029 1:CAS:528:DC%2BC3MXntVygt7Y%3D 10.1007/s12325-011-0007-3
-
Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28:334-340
-
(2011)
Adv Ther
, vol.28
, pp. 334-340
-
-
Chinot, O.L.1
De La Motte, R.T.2
Moore, N.3
Zeaiter, A.4
Das, A.5
Phillips, H.6
Modrusan, Z.7
Cloughesy, T.8
-
26
-
-
84863413030
-
Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma
-
22428052 1:CAS:528:DC%2BC38XksFGrsL8%3D 10.1371/journal.pone.0033449
-
Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M (2012) Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS ONE 7:e33449
-
(2012)
PLoS ONE
, vol.7
, pp. 33449
-
-
Christians, A.1
Hartmann, C.2
Benner, A.3
Meyer, J.4
Von Deimling, A.5
Weller, M.6
Wick, W.7
Weiler, M.8
-
27
-
-
84860247330
-
The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma
-
22440258 1:CAS:528:DC%2BC38XnsF2ktb4%3D 10.1016/j.ajpath.2012.01.040
-
Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, Rong Y, Kurc T, Van Meir EG, Saltz JH, Moreno CS, Brat DJ (2012) The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 180:2108-2119
-
(2012)
Am J Pathol
, vol.180
, pp. 2108-2119
-
-
Cooper, L.A.1
Gutman, D.A.2
Chisolm, C.3
Appin, C.4
Kong, J.5
Rong, Y.6
Kurc, T.7
Van Meir, E.G.8
Saltz, J.H.9
Moreno, C.S.10
Brat, D.J.11
-
28
-
-
50649103493
-
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
-
18581057 10.1007/s11060-008-9637-y 1:CAS:528:DC%2BD1cXht1ejtLbK
-
de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK (2008) Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90:89-97
-
(2008)
J Neurooncol
, vol.90
, pp. 89-97
-
-
De Groot, J.F.1
Gilbert, M.R.2
Aldape, K.3
Hess, K.R.4
Hanna, T.A.5
Ictech, S.6
Groves, M.D.7
Conrad, C.8
Colman, H.9
Puduvalli, V.K.10
Levin, V.11
Yung, W.K.12
-
29
-
-
33745845114
-
Role of ABC transporters in the chemoresistance of human gliomas
-
16918310 1:CAS:528:DC%2BD28XnslCmsLw%3D 10.2174/156800906777723930
-
Decleves X, Amiel A, Delattre JY, Scherrmann JM (2006) Role of ABC transporters in the chemoresistance of human gliomas. Curr Cancer Drug Targets 6:433-445
-
(2006)
Curr Cancer Drug Targets
, vol.6
, pp. 433-445
-
-
Decleves, X.1
Amiel, A.2
Delattre, J.Y.3
Scherrmann, J.M.4
-
30
-
-
84863154888
-
Targeting EGF receptor variant III: Tumor-specific peptide vaccination for malignant gliomas
-
22309662 10.1586/erv.11.177 1:CAS:528:DC%2BC38XitFWhtb8%3D
-
Del Vecchio CA, Li G, Wong AJ (2012) Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert Rev Vaccines 11:133-144
-
(2012)
Expert Rev Vaccines
, vol.11
, pp. 133-144
-
-
Del Vecchio, C.A.1
Li, G.2
Wong, A.J.3
-
31
-
-
79952907554
-
Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme
-
21154166
-
Del Vecchio CA, Wong AJ (2010) Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther 12:741-754
-
(2010)
Curr Opin Mol Ther
, vol.12
, pp. 741-754
-
-
Del Vecchio, C.A.1
Wong, A.J.2
-
32
-
-
84857830005
-
Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes
-
21722156 1:CAS:528:DC%2BC38Xmt1Snurg%3D 10.1111/j.1365-2990.2011.01207.x
-
Delic S, Lottmann N, Jetschke K, Reifenberger G, Riemenschneider MJ (2012) Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes. Neuropathol Appl Neurobiol 38:201-212
-
(2012)
Neuropathol Appl Neurobiol
, vol.38
, pp. 201-212
-
-
Delic, S.1
Lottmann, N.2
Jetschke, K.3
Reifenberger, G.4
Riemenschneider, M.J.5
-
33
-
-
84872198988
-
A Phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
-
22687197 10.1016/j.ijrobp.2012.04.017 1:CAS:528:DC%2BC38XosFWgtrc%3D
-
Den RB, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, Lawrence YR, Hegarty S, Hyslop T, Andrews DW, Glass J, Friedman DP, Green MR, Camphausen K, Dicker AP (2012) A Phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 85:321-328
-
(2012)
Int J Radiat Oncol Biol Phys
, vol.85
, pp. 321-328
-
-
Den, R.B.1
Kamrava, M.2
Sheng, Z.3
Werner-Wasik, M.4
Dougherty, E.5
Marinucchi, M.6
Lawrence, Y.R.7
Hegarty, S.8
Hyslop, T.9
Andrews, D.W.10
Glass, J.11
Friedman, D.P.12
Green, M.R.13
Camphausen, K.14
Dicker, A.P.15
-
34
-
-
77955653868
-
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
-
20705518 10.1016/S1474-4422(10)70181-2
-
Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ (2010) Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 9:906-920
-
(2010)
Lancet Neurol
, vol.9
, pp. 906-920
-
-
Dhermain, F.G.1
Hau, P.2
Lanfermann, H.3
Jacobs, A.H.4
Van Den Bent, M.J.5
-
35
-
-
77955922743
-
Phase i study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma
-
20137866 1:CAS:528:DC%2BC3cXhtVaqtr7E 10.1016/j.ijrobp.2009.07.1741
-
Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY (2010) Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 78:85-90
-
(2010)
Int J Radiat Oncol Biol Phys
, vol.78
, pp. 85-90
-
-
Drappatz, J.1
Norden, A.D.2
Wong, E.T.3
Doherty, L.M.4
Lafrankie, D.C.5
Ciampa, A.6
Kesari, S.7
Sceppa, C.8
Gerard, M.9
Phan, P.10
Schiff, D.11
Batchelor, T.T.12
Ligon, K.L.13
Young, G.14
Muzikansky, A.15
Weiss, S.E.16
Wen, P.Y.17
-
36
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
11287973 1:CAS:528:DC%2BD3MXivFGnu7o%3D 10.1056/NEJM200104053441402
-
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042
-
(2001)
N Engl J Med
, vol.344
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
Resta, D.J.4
Reese, S.F.5
Ford, J.M.6
Capdeville, R.7
Talpaz, M.8
-
37
-
-
0035810147
-
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
-
11287972 1:CAS:528:DC%2BD3MXivFGnu70%3D 10.1056/NEJM200104053441401
-
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037
-
(2001)
N Engl J Med
, vol.344
, pp. 1031-1037
-
-
Druker, B.J.1
Talpaz, M.2
Resta, D.J.3
Peng, B.4
Buchdunger, E.5
Ford, J.M.6
Lydon, N.B.7
Kantarjian, H.8
Capdeville, R.9
Ohno-Jones, S.10
Sawyers, C.L.11
-
38
-
-
84866743133
-
Phase II trial of radiosurgery to magnetic resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma multiforme
-
22445005 10.1016/j.ijrobp.2012.01.020
-
Einstein DB, Wessels B, Bangert B, Fu P, Nelson AD, Cohen M, Sagar S, Lewin J, Sloan A, Zheng Y, Williams J, Colussi V, Vinkler R, Maciunas R (2012) Phase II trial of radiosurgery to magnetic resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 84:668-674
-
(2012)
Int J Radiat Oncol Biol Phys
, vol.84
, pp. 668-674
-
-
Einstein, D.B.1
Wessels, B.2
Bangert, B.3
Fu, P.4
Nelson, A.D.5
Cohen, M.6
Sagar, S.7
Lewin, J.8
Sloan, A.9
Zheng, Y.10
Williams, J.11
Colussi, V.12
Vinkler, R.13
Maciunas, R.14
-
39
-
-
79960519108
-
Finding the anaplastic focus in diffuse gliomas: The value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence
-
21507562 10.1016/j.clineuro.2011.03.008
-
Ewelt C, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, Stoffels G, Stummer W (2011) Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg 113:541-547
-
(2011)
Clin Neurol Neurosurg
, vol.113
, pp. 541-547
-
-
Ewelt, C.1
Floeth, F.W.2
Felsberg, J.3
Steiger, H.J.4
Sabel, M.5
Langen, K.J.6
Stoffels, G.7
Stummer, W.8
-
40
-
-
1342339254
-
Oligodendroglial tumors: Refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival
-
15193024 1:CAS:528:DC%2BD2cXkvFCgs7Y%3D 10.1111/j.1750-3639.2004.tb00044. x
-
Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G (2004) Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14:121-130
-
(2004)
Brain Pathol
, vol.14
, pp. 121-130
-
-
Felsberg, J.1
Erkwoh, A.2
Sabel, M.C.3
Kirsch, L.4
Fimmers, R.5
Blaschke, B.6
Schlegel, U.7
Schramm, J.8
Wiestler, O.D.9
Reifenberger, G.10
-
41
-
-
34248550985
-
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
-
17440065 1:CAS:528:DC%2BD2sXkt1Kju70%3D 10.1158/0008-5472.CAN-06-4238
-
Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67:3560-3564
-
(2007)
Cancer Res
, vol.67
, pp. 3560-3564
-
-
Folkins, C.1
Man, S.2
Xu, P.3
Shaked, Y.4
Hicklin, D.J.5
Kerbel, R.S.6
-
42
-
-
70350461699
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
-
19720927 1:CAS:528:DC%2BD1MXhtlGgtbbM 10.1200/JCO.2008.19.8721
-
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
-
(2009)
J Clin Oncol
, vol.27
, pp. 4733-4740
-
-
Friedman, H.S.1
Prados, M.D.2
Wen, P.Y.3
Mikkelsen, T.4
Schiff, D.5
Abrey, L.E.6
Yung, W.K.7
Paleologos, N.8
Nicholas, M.K.9
Jensen, R.10
Vredenburgh, J.11
Huang, J.12
Zheng, M.13
Cloughesy, T.14
-
43
-
-
23944453425
-
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study
-
15998902 1:CAS:528:DC%2BD2MXpslOrtLw%3D 10.1200/JCO.2005.23.622
-
Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304
-
(2005)
J Clin Oncol
, vol.23
, pp. 5294-5304
-
-
Galanis, E.1
Buckner, J.C.2
Maurer, M.J.3
Kreisberg, J.I.4
Ballman, K.5
Boni, J.6
Peralba, J.M.7
Jenkins, R.B.8
Dakhil, S.R.9
Morton, R.F.10
Jaeckle, K.A.11
Scheithauer, B.W.12
Dancey, J.13
Hidalgo, M.14
Walsh, D.J.15
-
44
-
-
84863327274
-
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells
-
Epub ahead of print
-
Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G and Weller M (2012) Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem [Epub ahead of print]
-
(2012)
J Neurochem
-
-
Happold, C.1
Roth, P.2
Wick, W.3
Schmidt, N.4
Florea, A.M.5
Silginer, M.6
Reifenberger, G.7
Weller, M.8
-
45
-
-
0034519441
-
Local drug delivery
-
10841189 1:CAS:528:DC%2BD3cXot1WgtLo%3D 10.1097/00001622-200005000-00001
-
Haroun RI, Brem H (2000) Local drug delivery. Curr Opin Oncol 12:187-193
-
(2000)
Curr Opin Oncol
, vol.12
, pp. 187-193
-
-
Haroun, R.I.1
Brem, H.2
-
46
-
-
78651082266
-
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas
-
21088844 10.1007/s00401-010-0781-z
-
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707-718
-
(2010)
Acta Neuropathol
, vol.120
, pp. 707-718
-
-
Hartmann, C.1
Hentschel, B.2
Wick, W.3
Capper, D.4
Felsberg, J.5
Simon, M.6
Westphal, M.7
Schackert, G.8
Meyermann, R.9
Pietsch, T.10
Reifenberger, G.11
Weller, M.12
Loeffler, M.13
Von Deimling, A.14
-
47
-
-
71949123241
-
Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides
-
19895249 1:CAS:528:DC%2BD1MXhtl2rsbrL 10.1586/era.09.138
-
Hau P, Jachimczak P, Bogdahn U (2009) Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides. Expert Rev Anticancer Ther 9:1663-1674
-
(2009)
Expert Rev Anticancer Ther
, vol.9
, pp. 1663-1674
-
-
Hau, P.1
Jachimczak, P.2
Bogdahn, U.3
-
48
-
-
84855245343
-
TGF-beta2 signaling in high-grade gliomas
-
21619538 1:CAS:528:DC%2BC38XovV2gsw%3D%3D 10.2174/138920111798808347
-
Hau P, Jachimczak P, Schlaier J, Bogdahn U (2011) TGF-beta2 signaling in high-grade gliomas. Curr Pharm Biotechnol 12:2150-2157
-
(2011)
Curr Pharm Biotechnol
, vol.12
, pp. 2150-2157
-
-
Hau, P.1
Jachimczak, P.2
Schlaier, J.3
Bogdahn, U.4
-
49
-
-
34547187636
-
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant glioma: From preclinical to Phase I/II studies
-
17638524 1:CAS:528:DC%2BD2sXnsl2nsro%3D 10.1089/oli.2006.0053
-
Hau P, Jachimczak P, Schlingensiepen R, Stauder G, Bogdahn U, Schlingensiepen K et al (2007) Inhibition of TGF-beta2 with AP 12009 in recurrent malignant glioma: from preclinical to Phase I/II studies. Oligonucleotides 17:201-212
-
(2007)
Oligonucleotides
, vol.17
, pp. 201-212
-
-
Hau, P.1
Jachimczak, P.2
Schlingensiepen, R.3
Stauder, G.4
Bogdahn, U.5
Schlingensiepen, K.6
-
50
-
-
33847400183
-
MGMT methylation status: The advent of stratified therapy in glioblastoma?
-
17325429 1:CAS:528:DC%2BD2sXltFWisb0%3D 10.1155/2007/159242
-
Hau P, Stupp R, Hegi ME (2007) MGMT methylation status: the advent of stratified therapy in glioblastoma? Dis Markers 23:97-104
-
(2007)
Dis Markers
, vol.23
, pp. 97-104
-
-
Hau, P.1
Stupp, R.2
Hegi, M.E.3
-
51
-
-
20044372154
-
MGMT gene silencing and benefit from temozolomide in glioblastoma
-
15758010 1:CAS:528:DC%2BD2MXit1Wktro%3D 10.1056/NEJMoa043331
-
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
-
(2005)
N Engl J Med
, vol.352
, pp. 997-1003
-
-
Hegi, M.E.1
Diserens, A.C.2
Gorlia, T.3
Hamou, M.F.4
De Tribolet, N.5
Weller, M.6
Kros, J.M.7
Hainfellner, J.A.8
Mason, W.9
Mariani, L.10
Bromberg, J.E.11
Hau, P.12
Mirimanoff, R.O.13
Cairncross, J.G.14
Janzer, R.C.15
Stupp, R.16
-
52
-
-
39149097490
-
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
-
18079360 1:CAS:528:DC%2BD1cXivFKgtr0%3D 10.1215/15228517-2007-046
-
Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH (2008) Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 10:98-103
-
(2008)
Neuro Oncol
, vol.10
, pp. 98-103
-
-
Heimberger, A.B.1
Sun, W.2
Hussain, S.F.3
Dey, M.4
Crutcher, L.5
Aldape, K.6
Gilbert, M.7
Hassenbusch, S.J.8
Sawaya, R.9
Schmittling, B.10
Archer, G.E.11
Mitchell, D.A.12
Bigner, D.D.13
Sampson, J.H.14
-
53
-
-
79851509146
-
Biobanking: The foundation of personalized medicine
-
21076300 10.1097/CCO.0b013e32834161b8
-
Hewitt RE (2011) Biobanking: the foundation of personalized medicine. Curr Opin Oncol 23:112-119
-
(2011)
Curr Opin Oncol
, vol.23
, pp. 112-119
-
-
Hewitt, R.E.1
-
54
-
-
67849124654
-
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency
-
19664991 1:CAS:528:DC%2BD1MXhsVCiu77P 10.1016/j.stem.2009.05.019
-
Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Satyal S, Wang X, Clarke MF, Lewicki J, Gurney A (2009) DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5:168-177
-
(2009)
Cell Stem Cell
, vol.5
, pp. 168-177
-
-
Hoey, T.1
Yen, W.C.2
Axelrod, F.3
Basi, J.4
Donigian, L.5
Dylla, S.6
Fitch-Bruhns, M.7
Lazetic, S.8
Park, I.K.9
Sato, A.10
Satyal, S.11
Wang, X.12
Clarke, M.F.13
Lewicki, J.14
Gurney, A.15
-
55
-
-
84867856045
-
Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas
-
22930388 1:CAS:528:DC%2BC38XhsFagsrrN 10.1007/s11060-012-0968-3
-
Holdhoff M, Ye X, Blakeley JO, Blair L, Burger PC, Grossman SA, Diaz LA Jr (2012) Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol 110:279-285
-
(2012)
J Neurooncol
, vol.110
, pp. 279-285
-
-
Holdhoff, M.1
Ye, X.2
Blakeley, J.O.3
Blair, L.4
Burger, P.C.5
Grossman, S.A.6
Diaz, Jr.L.A.7
-
56
-
-
85027926464
-
MicroRNAs in brain tumors: A new diagnostic and therapeutic perspective?
-
21739238 1:CAS:528:DC%2BC3MXhsFOjt7nO 10.1007/s12035-011-8197-x
-
Hummel R, Maurer J, Haier J (2011) MicroRNAs in brain tumors: a new diagnostic and therapeutic perspective? Mol Neurobiol 44:223-234
-
(2011)
Mol Neurobiol
, vol.44
, pp. 223-234
-
-
Hummel, R.1
Maurer, J.2
Haier, J.3
-
57
-
-
33646256145
-
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy
-
16618716 1:CAS:528:DC%2BD28XjsFSlsbw%3D 10.1158/0008-5472.CAN-06-0127
-
Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O'Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C, Varian J, West S, Widaa S, Yates A, Easton DF, Riggins G, Roy JE, Levine KK, Mueller W, Batchelor TT, Louis DN, Stratton MR, Futreal PA, Wooster R (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66:3987-3991
-
(2006)
Cancer Res
, vol.66
, pp. 3987-3991
-
-
Hunter, C.1
Smith, R.2
Cahill, D.P.3
Stephens, P.4
Stevens, C.5
Teague, J.6
Greenman, C.7
Edkins, S.8
Bignell, G.9
Davies, H.10
O'Meara, S.11
Parker, A.12
Avis, T.13
Barthorpe, S.14
Brackenbury, L.15
Buck, G.16
Butler, A.17
Clements, J.18
Cole, J.19
Dicks, E.20
Forbes, S.21
Gorton, M.22
Gray, K.23
Halliday, K.24
Harrison, R.25
Hills, K.26
Hinton, J.27
Jenkinson, A.28
Jones, D.29
Kosmidou, V.30
Laman, R.31
Lugg, R.32
Menzies, A.33
Perry, J.34
Petty, R.35
Raine, K.36
Richardson, D.37
Shepherd, R.38
Small, A.39
Solomon, H.40
Tofts, C.41
Varian, J.42
West, S.43
Widaa, S.44
Yates, A.45
Easton, D.F.46
Riggins, G.47
Roy, J.E.48
Levine, K.K.49
Mueller, W.50
Batchelor, T.T.51
Louis, D.N.52
Stratton, M.R.53
Futreal, P.A.54
Wooster, R.55
more..
-
58
-
-
68349116524
-
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
-
19435942 1:CAS:528:DC%2BD1MXhtV2qur%2FF 10.1215/15228517-2009-025
-
Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341-347
-
(2009)
Neuro Oncol
, vol.11
, pp. 341-347
-
-
Ichimura, K.1
Pearson, D.M.2
Kocialkowski, S.3
Backlund, L.M.4
Chan, R.5
Jones, D.T.6
Collins, V.P.7
-
59
-
-
78149492402
-
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
-
20200024 1:CAS:528:DC%2BC3cXpvFSlt70%3D 10.1093/neuonc/noq025
-
Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 12:855-861
-
(2010)
Neuro Oncol
, vol.12
, pp. 855-861
-
-
Iwamoto, F.M.1
Lamborn, K.R.2
Robins, H.I.3
Mehta, M.P.4
Chang, S.M.5
Butowski, N.A.6
Deangelis, L.M.7
Abrey, L.E.8
Zhang, W.T.9
Prados, M.D.10
Fine, H.A.11
-
60
-
-
34447632643
-
Angiogenesis in brain tumours
-
17643088 1:CAS:528:DC%2BD2sXnvFKntbk%3D 10.1038/nrn2175
-
Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622
-
(2007)
Nat Rev Neurosci
, vol.8
, pp. 610-622
-
-
Jain, R.K.1
Di Tomaso, E.2
Duda, D.G.3
Loeffler, J.S.4
Sorensen, A.G.5
Batchelor, T.T.6
-
61
-
-
0035552282
-
The molecular genetics of therapeutic resistance in malignant astrocytomas
-
12174677 1:CAS:528:DC%2BD38XitVGgsrw%3D 10.2165/00129785-200101020-00002
-
Jennings MT, Iyengar S (2001) The molecular genetics of therapeutic resistance in malignant astrocytomas. Am J Pharmacogenomics 1:93-99
-
(2001)
Am J Pharmacogenomics
, vol.1
, pp. 93-99
-
-
Jennings, M.T.1
Iyengar, S.2
-
62
-
-
55349107544
-
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas
-
18974108 1:CAS:528:DC%2BD1cXhtlSktbfM 10.1158/0008-5472.CAN-08-2097
-
Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673-8677
-
(2008)
Cancer Res
, vol.68
, pp. 8673-8677
-
-
Jones, D.T.1
Kocialkowski, S.2
Liu, L.3
Pearson, D.M.4
Backlund, L.M.5
Ichimura, K.6
Collins, V.P.7
-
63
-
-
67349219657
-
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma
-
19363522 1:CAS:528:DC%2BD1MXksVeluro%3D 10.1038/onc.2009.73
-
Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP (2009) Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28:2119-2123
-
(2009)
Oncogene
, vol.28
, pp. 2119-2123
-
-
Jones, D.T.1
Kocialkowski, S.2
Liu, L.3
Pearson, D.M.4
Ichimura, K.5
Collins, V.P.6
-
64
-
-
84863796187
-
Bevacizumab for the treatment of high-grade glioma
-
22663137 1:CAS:528:DC%2BC38XhtVemurvM 10.1517/14712598.2012.694422
-
Khasraw M, Simeonovic M, Grommes C (2012) Bevacizumab for the treatment of high-grade glioma. Expert Opin Biol Ther 12:1101-1111
-
(2012)
Expert Opin Biol Ther
, vol.12
, pp. 1101-1111
-
-
Khasraw, M.1
Simeonovic, M.2
Grommes, C.3
-
65
-
-
79955514336
-
A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs
-
21385897 1:CAS:528:DC%2BC3MXltlGhurs%3D 10.1158/0008-5472.CAN-10-4117
-
Kim TM, Huang W, Park R, Park PJ, Johnson MD (2011) A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 71:3387-3399
-
(2011)
Cancer Res
, vol.71
, pp. 3387-3399
-
-
Kim, T.M.1
Huang, W.2
Park, R.3
Park, P.J.4
Johnson, M.D.5
-
66
-
-
0032601166
-
Primary and secondary glioblastomas: From concept to clinical diagnosis
-
11550301 1:STN:280:DC%2BD3MrgtFCktg%3D%3D
-
Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1:44-51
-
(1999)
Neuro Oncol
, vol.1
, pp. 44-51
-
-
Kleihues, P.1
Ohgaki, H.2
-
67
-
-
75849133697
-
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
-
20150385 1:CAS:528:DC%2BC3cXotFKitbg%3D 10.1093/neuonc/nop042
-
Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D, Fine HA (2010) A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol 12:181-189
-
(2010)
Neuro Oncol
, vol.12
, pp. 181-189
-
-
Kreisl, T.N.1
Kotliarova, S.2
Butman, J.A.3
Albert, P.S.4
Kim, L.5
Musib, L.6
Thornton, D.7
Fine, H.A.8
-
68
-
-
84869155416
-
A phase I/II trial of vandetanib for patients with recurrent malignant glioma
-
23099652 1:CAS:528:DC%2BC38XhslWktL7E 10.1093/neuonc/nos265
-
Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA (2012) A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol 14:1519-1526
-
(2012)
Neuro Oncol
, vol.14
, pp. 1519-1526
-
-
Kreisl, T.N.1
McNeill, K.A.2
Sul, J.3
Iwamoto, F.M.4
Shih, J.5
Fine, H.A.6
-
69
-
-
34249915554
-
Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome
-
17549014 1:CAS:528:DC%2BD2sXnsFKmtLY%3D 10.1097/01.jnen.0000263869.84188. 72
-
Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mork SJ, Paetau A, Reifenberger G, van den Bent MJ (2007) Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66:545-551
-
(2007)
J Neuropathol Exp Neurol
, vol.66
, pp. 545-551
-
-
Kros, J.M.1
Gorlia, T.2
Kouwenhoven, M.C.3
Zheng, P.P.4
Collins, V.P.5
Figarella-Branger, D.6
Giangaspero, F.7
Giannini, C.8
Mokhtari, K.9
Mork, S.J.10
Paetau, A.11
Reifenberger, G.12
Van Den Bent, M.J.13
-
70
-
-
84874527416
-
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome
-
23328811 1:CAS:528:DC%2BC3sXjtV2qtrY%3D 10.1093/neuonc/nos308
-
Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, Ormiston L, Ancheta K, Hanna R, Miller P, Piccioni D, Ellingson BM, Buchanan C, Mischel PS, Nghiemphu PL, Green R, Wang HJ, Pope WB, Liau LM, Elashoff RM, Cloughesy TF, Yong WH, Lai A (2013) Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol 15:370-381
-
(2013)
Neuro Oncol
, vol.15
, pp. 370-381
-
-
Lalezari, S.1
Chou, A.P.2
Tran, A.3
Solis, O.E.4
Khanlou, N.5
Chen, W.6
Li, S.7
Carrillo, J.A.8
Chowdhury, R.9
Selfridge, J.10
Sanchez, D.E.11
Wilson, R.W.12
Zurayk, M.13
Lalezari, J.14
Lou, J.J.15
Ormiston, L.16
Ancheta, K.17
Hanna, R.18
Miller, P.19
Piccioni, D.20
Ellingson, B.M.21
Buchanan, C.22
Mischel, P.S.23
Nghiemphu, P.L.24
Green, R.25
Wang, H.J.26
Pope, W.B.27
Liau, L.M.28
Elashoff, R.M.29
Cloughesy, T.F.30
Yong, W.H.31
Lai, A.32
more..
-
71
-
-
0347378566
-
Invasion as limitation to anti-angiogenic glioma therapy
-
14531575 1:STN:280:DC%2BD3svmvFeqsQ%3D%3D
-
Lamszus K, Kunkel P, Westphal M (2003) Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 88:169-177
-
(2003)
Acta Neurochir Suppl
, vol.88
, pp. 169-177
-
-
Lamszus, K.1
Kunkel, P.2
Westphal, M.3
-
72
-
-
79960846309
-
SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation
-
21590492 1:CAS:528:DC%2BC3MXovFCksbw%3D 10.1007/s00401-011-0832-0
-
Lindemann C, Hackmann O, Delic S, Schmidt N, Reifenberger G, Riemenschneider MJ (2011) SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol 122:241-251
-
(2011)
Acta Neuropathol
, vol.122
, pp. 241-251
-
-
Lindemann, C.1
Hackmann, O.2
Delic, S.3
Schmidt, N.4
Reifenberger, G.5
Riemenschneider, M.J.6
-
73
-
-
77950221879
-
Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin
-
20145155 1:CAS:528:DC%2BC3cXisFWis74%3D 10.1158/0008-5472.CAN-09-1707
-
Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U, Wischhusen J, Spang R, Storch A, Beier CP (2010) Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 70:2030-2040
-
(2010)
Cancer Res
, vol.70
, pp. 2030-2040
-
-
Lottaz, C.1
Beier, D.2
Meyer, K.3
Kumar, P.4
Hermann, A.5
Schwarz, J.6
Junker, M.7
Oefner, P.J.8
Bogdahn, U.9
Wischhusen, J.10
Spang, R.11
Storch, A.12
Beier, C.P.13
-
74
-
-
33645732219
-
Molecular pathology of malignant gliomas
-
18039109 1:CAS:528:DC%2BD28XktVOitbw%3D 10.1146/annurev.pathol.1.110304. 100043
-
Louis DN (2006) Molecular pathology of malignant gliomas. Annu Rev Pathol 1:97-117
-
(2006)
Annu Rev Pathol
, vol.1
, pp. 97-117
-
-
Louis, D.N.1
-
75
-
-
84878362165
-
The next step in brain tumor classification: "let us now praise famous men". or molecules?
-
23151844 10.1007/s00401-012-1067-4
-
Louis DN (2012) The next step in brain tumor classification: "Let us now praise famous men". or molecules? Acta Neuropathol 124:761-762
-
(2012)
Acta Neuropathol
, vol.124
, pp. 761-762
-
-
Louis, D.N.1
-
77
-
-
42149132635
-
Chemoresistance in gliomas
-
18259841 1:CAS:528:DC%2BD1cXkvVOhsbs%3D 10.1007/s11010-008-9722-8
-
Lu C, Shervington A (2008) Chemoresistance in gliomas. Mol Cell Biochem 312:71-80
-
(2008)
Mol Cell Biochem
, vol.312
, pp. 71-80
-
-
Lu, C.1
Shervington, A.2
-
78
-
-
84858796262
-
IDH mutation impairs histone demethylation and results in a block to cell differentiation
-
22343901 1:CAS:528:DC%2BC38XisVKks74%3D 10.1038/nature10860
-
Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-478
-
(2012)
Nature
, vol.483
, pp. 474-478
-
-
Lu, C.1
Ward, P.S.2
Kapoor, G.S.3
Rohle, D.4
Turcan, S.5
Abdel-Wahab, O.6
Edwards, C.R.7
Khanin, R.8
Figueroa, M.E.9
Melnick, A.10
Wellen, K.E.11
O'Rourke, D.M.12
Berger, S.L.13
Chan, T.A.14
Levine, R.L.15
Mellinghoff, I.K.16
Thompson, C.B.17
-
79
-
-
0030883778
-
Molecular genetic evidence for subtypes of oligoastrocytomas
-
9329453 1:CAS:528:DyaK2sXmvVyku7Y%3D 10.1097/00005072-199710000-00003
-
Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von Deimling A (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56:1098-1104
-
(1997)
J Neuropathol Exp Neurol
, vol.56
, pp. 1098-1104
-
-
Maintz, D.1
Fiedler, K.2
Koopmann, J.3
Rollbrocker, B.4
Nechev, S.5
Lenartz, D.6
Stangl, A.P.7
Louis, D.N.8
Schramm, J.9
Wiestler, O.D.10
Von Deimling, A.11
-
80
-
-
84865558322
-
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial
-
22877848 10.1016/S1470-2045(12)70265-6 1:CAS:528:DC%2BC38Xhtlait7zE
-
Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916-926
-
(2012)
Lancet Oncol
, vol.13
, pp. 916-926
-
-
Malmstrom, A.1
Gronberg, B.H.2
Marosi, C.3
Stupp, R.4
Frappaz, D.5
Schultz, H.6
Abacioglu, U.7
Tavelin, B.8
Lhermitte, B.9
Hegi, M.E.10
Rosell, J.11
Henriksson, R.12
-
81
-
-
80054708001
-
Unraveling the glioma epigenome: From molecular mechanisms to novel biomarkers and therapeutic targets
-
21939466 1:CAS:528:DC%2BC3MXhsFCrsrfO 10.1111/j.1750-3639.2011.00536.x
-
Malzkorn B, Wolter M, Riemenschneider MJ, Reifenberger G (2011) Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets. Brain Pathol 21:619-632
-
(2011)
Brain Pathol
, vol.21
, pp. 619-632
-
-
Malzkorn, B.1
Wolter, M.2
Riemenschneider, M.J.3
Reifenberger, G.4
-
82
-
-
0034766198
-
Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: A cDNA microarray analysis
-
11716068 1:STN:280:DC%2BD3MnmvFyruw%3D%3D 10.1023/A:1012253317934
-
Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, Ross KR, Berens T, Coons SW, Watts G, Trent JM, Wei JS, Giese A, Berens ME (2001) Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J Neurooncol 53:161-176
-
(2001)
J Neurooncol
, vol.53
, pp. 161-176
-
-
Mariani, L.1
Beaudry, C.2
McDonough, W.S.3
Hoelzinger, D.B.4
Demuth, T.5
Ross, K.R.6
Berens, T.7
Coons, S.W.8
Watts, G.9
Trent, J.M.10
Wei, J.S.11
Giese, A.12
Berens, M.E.13
-
83
-
-
84860790212
-
Review: Molecular pathology in adult high-grade gliomas: From molecular diagnostics to target therapies
-
22098029 1:CAS:528:DC%2BC38XhtVyntL7F 10.1111/j.1365-2990.2011.01238.x
-
Masui K, Cloughesy TF, Mischel PS (2012) Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 38:271-291
-
(2012)
Neuropathol Appl Neurobiol
, vol.38
, pp. 271-291
-
-
Masui, K.1
Cloughesy, T.F.2
Mischel, P.S.3
-
84
-
-
77953049211
-
Distinction between glioma progression and post-radiation change by combined physiologic MR imaging
-
19834699 10.1007/s00234-009-0613-9
-
Matsusue E, Fink JR, Rockhill JK, Ogawa T, Maravilla KR (2010) Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 52:297-306
-
(2010)
Neuroradiology
, vol.52
, pp. 297-306
-
-
Matsusue, E.1
Fink, J.R.2
Rockhill, J.K.3
Ogawa, T.4
Maravilla, K.R.5
-
85
-
-
64249086909
-
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
-
19199360 1:CAS:528:DC%2BD1MXltlegurc%3D 10.1002/ijc.24240
-
Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124:2719-2727
-
(2009)
Int J Cancer
, vol.124
, pp. 2719-2727
-
-
Mikkelsen, T.1
Brodie, C.2
Finniss, S.3
Berens, M.E.4
Rennert, J.L.5
Nelson, K.6
Lemke, N.7
Brown, S.L.8
Hahn, D.9
Neuteboom, B.10
Goodman, S.L.11
-
86
-
-
0036310090
-
Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets
-
12107116 1:CAS:528:DC%2BD38Xlsl2ksLw%3D 10.1016/S0002-9440(10)64183-1
-
Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161:313-319
-
(2002)
Am J Pathol
, vol.161
, pp. 313-319
-
-
Mueller, W.1
Hartmann, C.2
Hoffmann, A.3
Lanksch, W.4
Kiwit, J.5
Tonn, J.6
Veelken, J.7
Schramm, J.8
Weller, M.9
Wiestler, O.D.10
Louis, D.N.11
Von Deimling, A.12
-
87
-
-
46449115281
-
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
-
18565887 1:CAS:528:DC%2BD1cXoslOqsLs%3D 10.1200/JCO.2007.15.7164
-
Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME (2008) Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26:3015-3024
-
(2008)
J Clin Oncol
, vol.26
, pp. 3015-3024
-
-
Murat, A.1
Migliavacca, E.2
Gorlia, T.3
Lambiv, W.L.4
Shay, T.5
Hamou, M.F.6
De Tribolet, N.7
Regli, L.8
Wick, W.9
Kouwenhoven, M.C.10
Hainfellner, J.A.11
Heppner, F.L.12
Dietrich, P.Y.13
Zimmer, Y.14
Cairncross, J.G.15
Janzer, R.C.16
Domany, E.17
Delorenzi, M.18
Stupp, R.19
Hegi, M.E.20
more..
-
88
-
-
84856271656
-
Phase i trial of sorafenib in patients with recurrent or progressive malignant glioma
-
21954442 1:CAS:528:DC%2BC38Xhtl2hsbrN 10.1093/neuonc/nor145
-
Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S, Grossman SA (2011) Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol 13:1324-1330
-
(2011)
Neuro Oncol
, vol.13
, pp. 1324-1330
-
-
Nabors, L.B.1
Supko, J.G.2
Rosenfeld, M.3
Chamberlain, M.4
Phuphanich, S.5
Batchelor, T.6
Desideri, S.7
Ye, X.8
Wright, J.9
Gujar, S.10
Grossman, S.A.11
-
89
-
-
79959795987
-
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
-
20872043 1:CAS:528:DC%2BC3MXnsFOjtb8%3D 10.1007/s11060-010-0402-7
-
Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen N, Michotte A, De Greve J (2011) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 103:491-501
-
(2011)
J Neurooncol
, vol.103
, pp. 491-501
-
-
Neyns, B.1
Sadones, J.2
Chaskis, C.3
Dujardin, M.4
Everaert, H.5
Lv, S.6
Duerinck, J.7
Tynninen, O.8
Nupponen, N.9
Michotte, A.10
De Greve, J.11
-
90
-
-
77952108366
-
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma
-
20399149 1:CAS:528:DC%2BC3cXmslKqsr0%3D 10.1016/j.ccr.2010.03.017
-
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522
-
(2010)
Cancer Cell
, vol.17
, pp. 510-522
-
-
Noushmehr, H.1
Weisenberger, D.J.2
Diefes, K.3
Phillips, H.S.4
Pujara, K.5
Berman, B.P.6
Pan, F.7
Pelloski, C.E.8
Sulman, E.P.9
Bhat, K.P.10
Verhaak, R.G.11
Hoadley, K.A.12
Hayes, D.N.13
Perou, C.M.14
Schmidt, H.K.15
Ding, L.16
Wilson, R.K.17
Van Den Berg, D.18
Shen, H.19
Bengtsson, H.20
Neuvial, P.21
Cope, L.M.22
Buckley, J.23
Herman, J.G.24
Baylin, S.B.25
Laird, P.W.26
Aldape, K.27
more..
-
91
-
-
34250877865
-
Genetic pathways to primary and secondary glioblastoma
-
17456751 1:CAS:528:DC%2BD2sXlvFCns74%3D 10.2353/ajpath.2007.070011
-
Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453
-
(2007)
Am J Pathol
, vol.170
, pp. 1445-1453
-
-
Ohgaki, H.1
Kleihues, P.2
-
92
-
-
79961151346
-
The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma
-
21829728 1:CAS:528:DC%2BC3MXhtFWitLnO 10.1371/journal.pone.0023332
-
Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T (2011) The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS ONE 6:e23332
-
(2011)
PLoS ONE
, vol.6
, pp. 23332
-
-
Ohka, F.1
Natsume, A.2
Motomura, K.3
Kishida, Y.4
Kondo, Y.5
Abe, T.6
Nakasu, Y.7
Namba, H.8
Wakai, K.9
Fukui, T.10
Momota, H.11
Iwami, K.12
Kinjo, S.13
Ito, M.14
Fujii, M.15
Wakabayashi, T.16
-
93
-
-
0037439688
-
Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas
-
12543796 1:CAS:528:DC%2BD3sXnt1Kruw%3D%3D
-
Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL, Louis DN (2003) Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res 63:413-416
-
(2003)
Cancer Res
, vol.63
, pp. 413-416
-
-
Okada, Y.1
Hurwitz, E.E.2
Esposito, J.M.3
Brower, M.A.4
Nutt, C.L.5
Louis, D.N.6
-
94
-
-
84879573827
-
Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: Results of a prospective pilot study
-
2013 Mar 3 [Epub ahead of print]
-
Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN and Brinkmann DH (2013) Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 2013 Mar 3 [Epub ahead of print]
-
(2013)
Neuro Oncol
-
-
Pafundi, D.H.1
Laack, N.N.2
Youland, R.S.3
Parney, I.F.4
Lowe, V.J.5
Giannini, C.6
Kemp, B.J.7
Grams, M.P.8
Morris, J.M.9
Hoover, J.M.10
Hu, L.S.11
Sarkaria, J.N.12
Brinkmann, D.H.13
-
95
-
-
84866364645
-
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma
-
22832897 1:CAS:528:DC%2BC38XhtlGmsbvE 10.1007/s11060-012-0943-z
-
Pan E, Yu D, Yue B, Potthast L, Chowdhary S, Smith P, Chamberlain M (2012) A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol 110:111-118
-
(2012)
J Neurooncol
, vol.110
, pp. 111-118
-
-
Pan, E.1
Yu, D.2
Yue, B.3
Potthast, L.4
Chowdhary, S.5
Smith, P.6
Chamberlain, M.7
-
96
-
-
52949127312
-
An integrated genomic analysis of human glioblastoma multiforme
-
18772396 1:CAS:528:DC%2BD1cXhtFCrtLrE 10.1126/science.1164382
-
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
-
(2008)
Science
, vol.321
, pp. 1807-1812
-
-
Parsons, D.W.1
Jones, S.2
Zhang, X.3
Lin, J.C.4
Leary, R.J.5
Angenendt, P.6
Mankoo, P.7
Carter, H.8
Siu, I.M.9
Gallia, G.L.10
Olivi, A.11
McLendon, R.12
Rasheed, B.A.13
Keir, S.14
Nikolskaya, T.15
Nikolsky, Y.16
Busam, D.A.17
Tekleab, H.18
Diaz, Jr.L.A.19
Hartigan, J.20
Smith, D.R.21
Strausberg, R.L.22
Marie, S.K.23
Shinjo, S.M.24
Yan, H.25
Riggins, G.J.26
Bigner, D.D.27
Karchin, R.28
Papadopoulos, N.29
Parmigiani, G.30
Vogelstein, B.31
Velculescu, V.E.32
Kinzler, K.W.33
more..
-
97
-
-
33644820339
-
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
-
16530701 1:CAS:528:DC%2BD28XivFWjtL4%3D 10.1016/j.ccr.2006.02.019
-
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173
-
(2006)
Cancer Cell
, vol.9
, pp. 157-173
-
-
Phillips, H.S.1
Kharbanda, S.2
Chen, R.3
Forrest, W.F.4
Soriano, R.H.5
Wu, T.D.6
Misra, A.7
Nigro, J.M.8
Colman, H.9
Soroceanu, L.10
Williams, P.M.11
Modrusan, Z.12
Feuerstein, B.G.13
Aldape, K.14
-
98
-
-
84862706167
-
Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study
-
22349712 1:STN:280:DC%2BC38vjsF2rug%3D%3D 10.1007/s00066-011-0060-5
-
Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, Galldiks N, Coenen HH, Kaiser HJ, Langen KJ, Eble MJ (2012) Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. Strahlenther Onkol 188:334-339
-
(2012)
Strahlenther Onkol
, vol.188
, pp. 334-339
-
-
Piroth, M.D.1
Pinkawa, M.2
Holy, R.3
Klotz, J.4
Schaar, S.5
Stoffels, G.6
Galldiks, N.7
Coenen, H.H.8
Kaiser, H.J.9
Langen, K.J.10
Eble, M.J.11
-
99
-
-
84878369037
-
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
-
23143192 10.1007/s00401-012-1066-5
-
Plate KH, Scholz A, Dumont DJ (2012) Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol 124:763-775
-
(2012)
Acta Neuropathol
, vol.124
, pp. 763-775
-
-
Plate, K.H.1
Scholz, A.2
Dumont, D.J.3
-
100
-
-
33646675851
-
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
-
16636248 1:CAS:528:DC%2BD28XjtFOrtLs%3D 10.1212/01.wnl.0000208958.29600. 87
-
Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258-1260
-
(2006)
Neurology
, vol.66
, pp. 1258-1260
-
-
Pope, W.B.1
Lai, A.2
Nghiemphu, P.3
Mischel, P.4
Cloughesy, T.F.5
-
101
-
-
59149086517
-
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma
-
19075262 1:CAS:528:DC%2BD1MXivFyjurk%3D 10.1200/JCO.2008.18.9639
-
Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27:579-584
-
(2009)
J Clin Oncol
, vol.27
, pp. 579-584
-
-
Prados, M.D.1
Chang, S.M.2
Butowski, N.3
Deboer, R.4
Parvataneni, R.5
Carliner, H.6
Kabuubi, P.7
Ayers-Ringler, J.8
Rabbitt, J.9
Page, M.10
Fedoroff, A.11
Sneed, P.K.12
Berger, M.S.13
McDermott, M.W.14
Parsa, A.T.15
Vandenberg, S.16
James, C.D.17
Lamborn, K.R.18
Stokoe, D.19
Haas-Kogan, D.A.20
more..
-
102
-
-
84859544365
-
A phase i study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054)
-
22291006 1:CAS:528:DC%2BC38Xhtl2hsrzL 10.1093/neuonc/nor221
-
Rampling R, Sanson M, Gorlia T, Lacombe D, Lai C, Gharib M, Taal W, Stoffregen C, Decker R, van den Bent MJ (2012) A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro Oncol 14:344-350
-
(2012)
Neuro Oncol
, vol.14
, pp. 344-350
-
-
Rampling, R.1
Sanson, M.2
Gorlia, T.3
Lacombe, D.4
Lai, C.5
Gharib, M.6
Taal, W.7
Stoffregen, C.8
Decker, R.9
Van Den Bent, M.J.10
-
103
-
-
77957561251
-
Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma
-
20711171 1:CAS:528:DC%2BC3cXht1emtLbK 10.1038/modpathol.2010.135
-
Rao SA, Santosh V, Somasundaram K (2010) Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 23:1404-1417
-
(2010)
Mod Pathol
, vol.23
, pp. 1404-1417
-
-
Rao, S.A.1
Santosh, V.2
Somasundaram, K.3
-
104
-
-
71649102124
-
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
-
19904263 1:CAS:528:DC%2BD1MXhsFaqtr7K 10.1038/sj.bjc.6605411
-
Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z (2009) Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101:1995-2004
-
(2009)
Br J Cancer
, vol.101
, pp. 1995-2004
-
-
Reardon, D.A.1
Dresemann, G.2
Taillibert, S.3
Campone, M.4
Van Den Bent, M.5
Clement, P.6
Blomquist, E.7
Gordower, L.8
Schultz, H.9
Raizer, J.10
Hau, P.11
Easaw, J.12
Gil, M.13
Tonn, J.14
Gijtenbeek, A.15
Schlegel, U.16
Bergstrom, P.17
Green, S.18
Weir, A.19
Nikolova, Z.20
more..
-
105
-
-
65649146868
-
Phase i pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
-
19248046 1:CAS:528:DC%2BD1MXlvFOhsr8%3D 10.1002/cncr.24213
-
Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ, Friedman HS (2009) Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 115:2188-2198
-
(2009)
Cancer
, vol.115
, pp. 2188-2198
-
-
Reardon, D.A.1
Egorin, M.J.2
Desjardins, A.3
Vredenburgh, J.J.4
Beumer, J.H.5
Lagattuta, T.F.6
Gururangan, S.7
Herndon II, J.E.8
Salvado, A.J.9
Friedman, H.S.10
-
106
-
-
33644830094
-
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme
-
16361636 1:CAS:528:DC%2BD28Xnt1ymsw%3D%3D 10.1200/JCO.2005.03.2185
-
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359-9368
-
(2005)
J Clin Oncol
, vol.23
, pp. 9359-9368
-
-
Reardon, D.A.1
Egorin, M.J.2
Quinn, J.A.3
Rich, J.N.4
Gururangan, S.5
Vredenburgh, J.J.6
Desjardins, A.7
Sathornsumetee, S.8
Provenzale, J.M.9
Herndon II, J.E.10
Dowell, J.M.11
Badruddoja, M.A.12
McLendon, R.E.13
Lagattuta, T.F.14
Kicielinski, K.P.15
Dresemann, G.16
Sampson, J.H.17
Friedman, A.H.18
Salvado, A.J.19
Friedman, H.S.20
more..
-
107
-
-
57149108506
-
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme
-
18981465 1:CAS:528:DC%2BD1MXmsVSrsw%3D%3D 10.1200/JCO.2008.16.7510
-
Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610-5617
-
(2008)
J Clin Oncol
, vol.26
, pp. 5610-5617
-
-
Reardon, D.A.1
Fink, K.L.2
Mikkelsen, T.3
Cloughesy, T.F.4
O'Neill, A.5
Plotkin, S.6
Glantz, M.7
Ravin, P.8
Raizer, J.J.9
Rich, K.M.10
Schiff, D.11
Shapiro, W.R.12
Burdette-Radoux, S.13
Dropcho, E.J.14
Wittemer, S.M.15
Nippgen, J.16
Picard, M.17
Nabors, L.B.18
-
108
-
-
51449124031
-
Cilengitide: An integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme
-
18616418 1:CAS:528:DC%2BD1cXos1Chs7k%3D 10.1517/13543784.17.8.1225
-
Reardon DA, Nabors LB, Stupp R, Mikkelsen T (2008) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17:1225-1235
-
(2008)
Expert Opin Investig Drugs
, vol.17
, pp. 1225-1235
-
-
Reardon, D.A.1
Nabors, L.B.2
Stupp, R.3
Mikkelsen, T.4
-
109
-
-
79953144790
-
Cilengitide: An RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in development for glioblastoma and other malignancies
-
21417900 1:CAS:528:DC%2BC3MXjsFCkur4%3D 10.2217/fon.11.8
-
Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R (2011) Cilengitide: an RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in development for glioblastoma and other malignancies. Future oncol 7:339-354
-
(2011)
Future Oncol
, vol.7
, pp. 339-354
-
-
Reardon, D.A.1
Neyns, B.2
Weller, M.3
Tonn, J.C.4
Nabors, L.B.5
Stupp, R.6
-
110
-
-
0037317982
-
Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology
-
12578221 1:CAS:528:DC%2BD3sXhsFaiurs%3D
-
Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111-126
-
(2003)
J Neuropathol Exp Neurol
, vol.62
, pp. 111-126
-
-
Reifenberger, G.1
Louis, D.N.2
-
111
-
-
0343819885
-
Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification
-
10626796 1:CAS:528:DC%2BD3cXktFyitQ%3D%3D
-
Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U, Reifenberger G (1999) Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53
-
(1999)
Cancer Res
, vol.59
, pp. 6091-6096
-
-
Riemenschneider, M.J.1
Buschges, R.2
Wolter, M.3
Reifenberger, J.4
Bostrom, J.5
Kraus, J.A.6
Schlegel, U.7
Reifenberger, G.8
-
112
-
-
78049317939
-
MGMT promoter methylation in malignant gliomas
-
20725792 10.1007/s11523-010-0153-6
-
Riemenschneider MJ, Hegi ME, Reifenberger G (2010) MGMT promoter methylation in malignant gliomas. Target Oncol 5:161-165
-
(2010)
Target Oncol
, vol.5
, pp. 161-165
-
-
Riemenschneider, M.J.1
Hegi, M.E.2
Reifenberger, G.3
-
114
-
-
27544459331
-
In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation
-
16251422 1:CAS:528:DC%2BD2MXht1agu73I 10.1016/S0002-9440(10)61225-4
-
Riemenschneider MJ, Mueller W, Betensky RA, Mohapatra G, Louis DN (2005) In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. Am J Pathol 167:1379-1387
-
(2005)
Am J Pathol
, vol.167
, pp. 1379-1387
-
-
Riemenschneider, M.J.1
Mueller, W.2
Betensky, R.A.3
Mohapatra, G.4
Louis, D.N.5
-
116
-
-
59649106565
-
Molecular neuropathology of gliomas
-
19333441 1:CAS:528:DC%2BD1MXitFOhu70%3D 10.3390/ijms10010184
-
Riemenschneider MJ, Reifenberger G (2009) Molecular neuropathology of gliomas. Int J Mol Sci 10:184-212
-
(2009)
Int J Mol Sci
, vol.10
, pp. 184-212
-
-
Riemenschneider, M.J.1
Reifenberger, G.2
-
117
-
-
77449099985
-
Molecular neuropathology of low-grade gliomas and its clinical impact
-
20102110 1:STN:280:DC%2BC3c%2FlsV2ktg%3D%3D 10.1007/978-3-211-99481-8-2
-
Riemenschneider MJ, Reifenberger G (2010) Molecular neuropathology of low-grade gliomas and its clinical impact. Adv Tech Stand Neurosurg 35:35-64
-
(2010)
Adv Tech Stand Neurosurg
, vol.35
, pp. 35-64
-
-
Riemenschneider, M.J.1
Reifenberger, G.2
-
118
-
-
74049085780
-
Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches
-
19741528 1:CAS:528:DC%2BD1MXhtlGisL3P 10.1097/WCO.0b013e32833245b0
-
Riemenschneider MJ, Reifenberger G (2009) Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. Curr Opin Neurol 22:619-624
-
(2009)
Curr Opin Neurol
, vol.22
, pp. 619-624
-
-
Riemenschneider, M.J.1
Reifenberger, G.2
-
119
-
-
84859963131
-
Addressing diffuse glioma as a systemic brain disease with single-cell analysis
-
22158715 10.1001/archneurol.2011.2910
-
Sahm F, Capper D, Jeibmann A, Habel A, Paulus W, Troost D, von Deimling A (2012) Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol 69:523-526
-
(2012)
Arch Neurol
, vol.69
, pp. 523-526
-
-
Sahm, F.1
Capper, D.2
Jeibmann, A.3
Habel, A.4
Paulus, W.5
Troost, D.6
Von Deimling, A.7
-
120
-
-
79960293686
-
MicroRNAs and glioblastoma: Roles in core signalling pathways and potential clinical implications
-
21435175 1:CAS:528:DC%2BC3MXpsV2hsLo%3D 10.1111/j.1582-4934.2011.01317.x
-
Sana J, Hajduch M, Michalek J, Vyzula R, Slaby O (2011) MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications. J Cell Mol Med 15:1636-1644
-
(2011)
J Cell Mol Med
, vol.15
, pp. 1636-1644
-
-
Sana, J.1
Hajduch, M.2
Michalek, J.3
Vyzula, R.4
Slaby, O.5
-
121
-
-
78349245231
-
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks
-
20921209 1:CAS:528:DC%2BC3cXhsVWmsbnI 10.1158/1078-0432.CCR-10-1453
-
Sarkaria JN, Galanis E, Wu W, Dietz AB, Kaufmann TJ, Gustafson MP, Brown PD, Uhm JH, Rao RD, Doyle L, Giannini C, Jaeckle KA, Buckner JC (2010) Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res 16:5573-5580
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5573-5580
-
-
Sarkaria, J.N.1
Galanis, E.2
Wu, W.3
Dietz, A.B.4
Kaufmann, T.J.5
Gustafson, M.P.6
Brown, P.D.7
Uhm, J.H.8
Rao, R.D.9
Doyle, L.10
Giannini, C.11
Jaeckle, K.A.12
Buckner, J.C.13
-
122
-
-
84867830537
-
Integrin inhibitor cilengitide for the treatment of glioblastoma: A brief overview of current clinical results
-
23060541 1:CAS:528:DC%2BC38Xhs1ygtbvN
-
Scaringi C, Minniti G, Caporello P, Enrici RM (2012) Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res 32:4213-4223
-
(2012)
Anticancer Res
, vol.32
, pp. 4213-4223
-
-
Scaringi, C.1
Minniti, G.2
Caporello, P.3
Enrici, R.M.4
-
123
-
-
79954441895
-
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
-
21274720 1:CAS:528:DC%2BC3MXhvVyrsrk%3D 10.1007/s00401-011-0802-6
-
Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397-405
-
(2011)
Acta Neuropathol
, vol.121
, pp. 397-405
-
-
Schindler, G.1
Capper, D.2
Meyer, J.3
Janzarik, W.4
Omran, H.5
Herold-Mende, C.6
Schmieder, K.7
Wesseling, P.8
Mawrin, C.9
Hasselblatt, M.10
Louis, D.N.11
Korshunov, A.12
Pfister, S.13
Hartmann, C.14
Paulus, W.15
Reifenberger, G.16
Von Deimling, A.17
-
124
-
-
30944437585
-
Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009
-
16377233 1:CAS:528:DC%2BD28Xos1Crsg%3D%3D 10.1016/j.cytogfr.2005.09.002
-
Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P (2006) Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev 17:129-139
-
(2006)
Cytokine Growth Factor Rev
, vol.17
, pp. 129-139
-
-
Schlingensiepen, K.H.1
Schlingensiepen, R.2
Steinbrecher, A.3
Hau, P.4
Bogdahn, U.5
Fischer-Blass, B.6
Jachimczak, P.7
-
125
-
-
22044456529
-
Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and safety
-
15989424 1:CAS:528:DC%2BD2MXls1Khu7s%3D 10.1089/oli.2005.15.94
-
Schlingensiepen R, Goldbrunner M, Szyrach MN, Stauder G, Jachimczak P, Bogdahn U, Schulmeyer F, Hau P, Schlingensiepen KH (2005) Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 15:94-104
-
(2005)
Oligonucleotides
, vol.15
, pp. 94-104
-
-
Schlingensiepen, R.1
Goldbrunner, M.2
Szyrach, M.N.3
Stauder, G.4
Jachimczak, P.5
Bogdahn, U.6
Schulmeyer, F.7
Hau, P.8
Schlingensiepen, K.H.9
-
126
-
-
77950838848
-
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha
-
20375133 10.1093/brain/awq042
-
Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nister M, Reifenberger G, Lundeberg J, Frisen J, Acker T (2010) A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133:983-995
-
(2010)
Brain
, vol.133
, pp. 983-995
-
-
Seidel, S.1
Garvalov, B.K.2
Wirta, V.3
Von Stechow, L.4
Schanzer, A.5
Meletis, K.6
Wolter, M.7
Sommerlad, D.8
Henze, A.T.9
Nister, M.10
Reifenberger, G.11
Lundeberg, J.12
Frisen, J.13
Acker, T.14
-
127
-
-
83455217896
-
Bevacizumab in glioblastoma multiforme
-
22149428 1:CAS:528:DC%2BC3MXhs1SgsLbL 10.1586/era.11.179
-
Specenier P (2012) Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther 12:9-18
-
(2012)
Expert Rev Anticancer Ther
, vol.12
, pp. 9-18
-
-
Specenier, P.1
-
128
-
-
77954924659
-
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma
-
20439646 1:CAS:528:DC%2BC3cXoslyktLs%3D 10.1200/JCO.2009.26.6650
-
Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28:2712-2718
-
(2010)
J Clin Oncol
, vol.28
, pp. 2712-2718
-
-
Stupp, R.1
Hegi, M.E.2
Neyns, B.3
Goldbrunner, R.4
Schlegel, U.5
Clement, P.M.6
Grabenbauer, G.G.7
Ochsenbein, A.F.8
Simon, M.9
Dietrich, P.Y.10
Pietsch, T.11
Hicking, C.12
Tonn, J.C.13
Diserens, A.C.14
Pica, A.15
Hermisson, M.16
Krueger, S.17
Picard, M.18
Weller, M.19
-
129
-
-
20044366163
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
-
15758009 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330
-
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
-
(2005)
N Engl J Med
, vol.352
, pp. 987-996
-
-
Stupp, R.1
Mason, W.P.2
Van Den Bent, M.J.3
Weller, M.4
Fisher, B.5
Taphoorn, M.J.6
Belanger, K.7
Brandes, A.A.8
Marosi, C.9
Bogdahn, U.10
Curschmann, J.11
Janzer, R.C.12
Ludwin, S.K.13
Gorlia, T.14
Allgeier, A.15
Lacombe, D.16
Cairncross, J.G.17
Eisenhauer, E.18
Mirimanoff, R.O.19
-
130
-
-
84867606428
-
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma
-
23079654 1:CAS:528:DC%2BC38XhsFWhsr%2FF 10.1016/j.ccr.2012.08.024
-
Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Fruhwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Durken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-437
-
(2012)
Cancer Cell
, vol.22
, pp. 425-437
-
-
Sturm, D.1
Witt, H.2
Hovestadt, V.3
Khuong-Quang, D.A.4
Jones, D.T.5
Konermann, C.6
Pfaff, E.7
Tonjes, M.8
Sill, M.9
Bender, S.10
Kool, M.11
Zapatka, M.12
Becker, N.13
Zucknick, M.14
Hielscher, T.15
Liu, X.Y.16
Fontebasso, A.M.17
Ryzhova, M.18
Albrecht, S.19
Jacob, K.20
Wolter, M.21
Ebinger, M.22
Schuhmann, M.U.23
Van Meter, T.24
Fruhwald, M.C.25
Hauch, H.26
Pekrun, A.27
Radlwimmer, B.28
Niehues, T.29
Von Komorowski, G.30
Durken, M.31
Kulozik, A.E.32
Madden, J.33
Donson, A.34
Foreman, N.K.35
Drissi, R.36
Fouladi, M.37
Scheurlen, W.38
Von Deimling, A.39
Monoranu, C.40
Roggendorf, W.41
Herold-Mende, C.42
Unterberg, A.43
Kramm, C.M.44
Felsberg, J.45
Hartmann, C.46
Wiestler, B.47
Wick, W.48
Milde, T.49
Witt, O.50
Lindroth, A.M.51
Schwartzentruber, J.52
Faury, D.53
Fleming, A.54
Zakrzewska, M.55
Liberski, P.P.56
Zakrzewski, K.57
Hauser, P.58
Garami, M.59
Klekner, A.60
Bognar, L.61
Morrissy, S.62
Cavalli, F.63
Taylor, M.D.64
Van Sluis, P.65
Koster, J.66
Versteeg, R.67
Volckmann, R.68
Mikkelsen, T.69
Aldape, K.70
Reifenberger, G.71
Collins, V.P.72
Majewski, J.73
Korshunov, A.74
Lichter, P.75
Plass, C.76
Jabado, N.77
Pfister, S.M.78
more..
-
131
-
-
80053531542
-
The role of integrins in glioma biology and anti-glioma therapies
-
21827415 1:CAS:528:DC%2BC3MXhtlGksrrE 10.2174/138161211797249189
-
Tabatabai G, Tonn JC, Stupp R, Weller M (2011) The role of integrins in glioma biology and anti-glioma therapies. Curr Pharm Des 17:2402-2410
-
(2011)
Curr Pharm des
, vol.17
, pp. 2402-2410
-
-
Tabatabai, G.1
Tonn, J.C.2
Stupp, R.3
Weller, M.4
-
132
-
-
78650749129
-
Molecular signatures classify astrocytic gliomas by IDH1 mutation status
-
20473936 1:CAS:528:DC%2BC3cXhs1ajs7jK 10.1002/ijc.25448
-
Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, Sabel MC, Hofmann S, Becker N, Hartmann C, Ohgaki H, von Deimling A, Wiestler OD, Hahn M, Lichter P, Reifenberger G, Radlwimmer B (2011) Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 128:1095-1103
-
(2011)
Int J Cancer
, vol.128
, pp. 1095-1103
-
-
Toedt, G.1
Barbus, S.2
Wolter, M.3
Felsberg, J.4
Tews, B.5
Blond, F.6
Sabel, M.C.7
Hofmann, S.8
Becker, N.9
Hartmann, C.10
Ohgaki, H.11
Von Deimling, A.12
Wiestler, O.D.13
Hahn, M.14
Lichter, P.15
Reifenberger, G.16
Radlwimmer, B.17
-
133
-
-
77956227086
-
Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician's perspective
-
20644945 10.1007/s00401-010-0725-7
-
van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 120:297-304
-
(2010)
Acta Neuropathol
, vol.120
, pp. 297-304
-
-
Van Den Bent, M.J.1
-
134
-
-
33745532038
-
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial
-
16782911 10.1200/JCO.2005.04.6078 1:CAS:528:DC%2BD28XntV2hurc%3D
-
van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722
-
(2006)
J Clin Oncol
, vol.24
, pp. 2715-2722
-
-
Van Den Bent, M.J.1
Carpentier, A.F.2
Brandes, A.A.3
Sanson, M.4
Taphoorn, M.J.5
Bernsen, H.J.6
Frenay, M.7
Tijssen, C.C.8
Grisold, W.9
Sipos, L.10
Haaxma-Reiche, H.11
Kros, J.M.12
Van Kouwenhoven, M.C.13
Vecht, C.J.14
Allgeier, A.15
Lacombe, D.16
Gorlia, T.17
-
135
-
-
77649122144
-
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
-
20160062 10.1158/1078-0432.CCR-09-2902 1:CAS:528:DC%2BC3cXisFSisLg%3D
-
van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1597-1604
-
-
Van Den Bent, M.J.1
Dubbink, H.J.2
Marie, Y.3
Brandes, A.A.4
Taphoorn, M.J.5
Wesseling, P.6
Frenay, M.7
Tijssen, C.C.8
Lacombe, D.9
Idbaih, A.10
Van Marion, R.11
Kros, J.M.12
Dinjens, W.N.13
Gorlia, T.14
Sanson, M.15
-
136
-
-
84864651706
-
Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD)
-
ASCO MEETING ABSTRACTS abstr 2
-
van den Bent MJ, Hoang-Xuan K, Brandes AA, Kros JM, Kouwenhoven MCM, Taphoorn MJB, Delattre JY, Bernsen HJJB, Frenay M, Tijssen C, Grisold W, Sipos L, Enting RH, Dinjens WNM, French P, Vecht CJ, Allgeier A, Lacombe DA and Gorlia T (2012) Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). J Clin Oncol 30:ASCO MEETING ABSTRACTS (suppl; abstr 2)
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Van Den Bent, M.J.1
Hoang-Xuan, K.2
Brandes, A.A.3
Kros, J.M.4
McM, K.5
Mjb, T.6
Delattre, J.Y.7
Hjjb, B.8
Frenay, M.9
Tijssen, C.10
Grisold, W.11
Sipos, L.12
Enting, R.H.13
Wnm, D.14
French, P.15
Vecht, C.J.16
Allgeier, A.17
Lacombe, D.A.18
Gorlia, T.19
-
137
-
-
0344863443
-
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
-
12599236 10.1002/cncr.11187
-
van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284
-
(2003)
Cancer
, vol.97
, pp. 1276-1284
-
-
Van Den Bent, M.J.1
Looijenga, L.H.2
Langenberg, K.3
Dinjens, W.4
Graveland, W.5
Uytdewilligen, L.6
Sillevis Smitt, P.A.7
Jenkins, R.B.8
Kros, J.M.9
-
138
-
-
73649123907
-
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
-
20129251 1:CAS:528:DC%2BC3cXkvFKgsL4%3D 10.1016/j.ccr.2009.12.020
-
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
-
(2010)
Cancer Cell
, vol.17
, pp. 98-110
-
-
Verhaak, R.G.1
Hoadley, K.A.2
Purdom, E.3
Wang, V.4
Qi, Y.5
Wilkerson, M.D.6
Miller, C.R.7
Ding, L.8
Golub, T.9
Mesirov, J.P.10
Alexe, G.11
Lawrence, M.12
O'Kelly, M.13
Tamayo, P.14
Weir, B.A.15
Gabriel, S.16
Winckler, W.17
Gupta, S.18
Jakkula, L.19
Feiler, H.S.20
Hodgson, J.G.21
James, C.D.22
Sarkaria, J.N.23
Brennan, C.24
Kahn, A.25
Spellman, P.T.26
Wilson, R.K.27
Speed, T.P.28
Gray, J.W.29
Meyerson, M.30
Getz, G.31
Perou, C.M.32
Hayes, D.N.33
more..
-
139
-
-
33745726808
-
Brain tumour stem cells
-
16723989 1:CAS:528:DC%2BD28XkvVylt78%3D 10.1038/nrc1889
-
Vescovi AL, Galli R, Reynolds BA (2006) Brain tumour stem cells. Nat Rev Cancer 6:425-436
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 425-436
-
-
Vescovi, A.L.1
Galli, R.2
Reynolds, B.A.3
-
140
-
-
33947191055
-
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
-
17317837 1:CAS:528:DC%2BD2sXhvF2htr8%3D 10.1158/1078-0432.CCR-06-2309
-
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1253-1259
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Herndon II, J.E.3
Dowell, J.M.4
Reardon, D.A.5
Quinn, J.A.6
Rich, J.N.7
Sathornsumetee, S.8
Gururangan, S.9
Wagner, M.10
Bigner, D.D.11
Friedman, A.H.12
Friedman, H.S.13
-
141
-
-
79953326958
-
Targeting BRAF in advanced melanoma: A first step toward manageable disease
-
21447722 1:CAS:528:DC%2BC3MXktVOisrw%3D 10.1158/1078-0432.CCR-10-0174
-
Vultur A, Villanueva J, Herlyn M (2011) Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res 17:1658-1663
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1658-1663
-
-
Vultur, A.1
Villanueva, J.2
Herlyn, M.3
-
142
-
-
84879564181
-
Technical issues of [(18)F]FET-PET imaging for radiation therapy planning in malignant glioma patients - A review
-
23061046 1:STN:280:DC%2BC3s%2Fks12gtA%3D%3D 10.3389/fonc.2012.00130
-
Walter F, la Fougere C, Belka C, Niyazi M (2012) Technical issues of [(18)F]FET-PET imaging for radiation therapy planning in malignant glioma patients - a review. Front Oncol 2:130
-
(2012)
Front Oncol
, vol.2
, pp. 130
-
-
Walter, F.1
La Fougere, C.2
Belka, C.3
Niyazi, M.4
-
143
-
-
78650677333
-
Biopsy targeting gliomas: Do functional imaging techniques identify similar target areas?
-
20829706 10.1097/RLI.0b013e3181ec9db0
-
Weber MA, Henze M, Tuttenberg J, Stieltjes B, Meissner M, Zimmer F, Burkholder I, Kroll A, Combs SE, Vogt-Schaden M, Giesel FL, Zoubaa S, Haberkorn U, Kauczor HU, Essig M (2010) Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? Invest Radiol 45:755-768
-
(2010)
Invest Radiol
, vol.45
, pp. 755-768
-
-
Weber, M.A.1
Henze, M.2
Tuttenberg, J.3
Stieltjes, B.4
Meissner, M.5
Zimmer, F.6
Burkholder, I.7
Kroll, A.8
Combs, S.E.9
Vogt-Schaden, M.10
Giesel, F.L.11
Zoubaa, S.12
Haberkorn, U.13
Kauczor, H.U.14
Essig, M.15
-
144
-
-
84874522500
-
Assessing the MGMT status in glioblastoma: One step forward, two steps back?
-
23430603 10.1093/neuonc/not014
-
Weller M (2013) Assessing the MGMT status in glioblastoma: one step forward, two steps back? Neuro Oncol 15:253-254
-
(2013)
Neuro Oncol
, vol.15
, pp. 253-254
-
-
Weller, M.1
-
145
-
-
79953282797
-
Bevacizumab does not increase the risk of remote relapse in malignant glioma
-
21446027 10.1002/ana.22336
-
Wick A, Dorner N, Schafer N, Hofer S, Heiland S, Schemmer D, Platten M, Weller M, Bendszus M, Wick W (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69:586-592
-
(2011)
Ann Neurol
, vol.69
, pp. 586-592
-
-
Wick, A.1
Dorner, N.2
Schafer, N.3
Hofer, S.4
Heiland, S.5
Schemmer, D.6
Platten, M.7
Weller, M.8
Bendszus, M.9
Wick, W.10
-
146
-
-
73349134695
-
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide
-
19901110 1:CAS:528:DC%2BC3cXhtVWis7g%3D 10.1200/JCO.2009.23.6497
-
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874-5880
-
(2009)
J Clin Oncol
, vol.27
, pp. 5874-5880
-
-
Wick, W.1
Hartmann, C.2
Engel, C.3
Stoffels, M.4
Felsberg, J.5
Stockhammer, F.6
Sabel, M.C.7
Koeppen, S.8
Ketter, R.9
Meyermann, R.10
Rapp, M.11
Meisner, C.12
Kortmann, R.D.13
Pietsch, T.14
Wiestler, O.D.15
Ernemann, U.16
Bamberg, M.17
Reifenberger, G.18
Von Deimling, A.19
Weller, M.20
more..
-
147
-
-
84863091424
-
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial
-
22578793 1:CAS:528:DC%2BC38XhtVShtrjK 10.1016/S1470-2045(12)70164-X
-
Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707-715
-
(2012)
Lancet Oncol
, vol.13
, pp. 707-715
-
-
Wick, W.1
Platten, M.2
Meisner, C.3
Felsberg, J.4
Tabatabai, G.5
Simon, M.6
Nikkhah, G.7
Papsdorf, K.8
Steinbach, J.P.9
Sabel, M.10
Combs, S.E.11
Vesper, J.12
Braun, C.13
Meixensberger, J.14
Ketter, R.15
Mayer-Steinacker, R.16
Reifenberger, G.17
Weller, M.18
-
148
-
-
77949891455
-
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma
-
20124186 1:CAS:528:DC%2BC3cXktF2ltb4%3D 10.1200/JCO.2009.23.2595
-
Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168-1174
-
(2010)
J Clin Oncol
, vol.28
, pp. 1168-1174
-
-
Wick, W.1
Puduvalli, V.K.2
Chamberlain, M.C.3
Van Den Bent, M.J.4
Carpentier, A.F.5
Cher, L.M.6
Mason, W.7
Weller, M.8
Hong, S.9
Musib, L.10
Liepa, A.M.11
Thornton, D.E.12
Fine, H.A.13
-
149
-
-
70350780180
-
New advances that enable identification of glioblastoma recurrence
-
19806145 10.1038/nrclinonc.2009.150
-
Yang I, Aghi MK (2009) New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol 6:648-657
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 648-657
-
-
Yang, I.1
Aghi, M.K.2
-
150
-
-
77149165396
-
Therapeutic targeting of EGFR in malignant gliomas
-
20148717 1:CAS:528:DC%2BC3cXhvF2rsrY%3D 10.1517/14728221003598948
-
Ye F, Gao Q, Cai MJ (2010) Therapeutic targeting of EGFR in malignant gliomas. Expert Opin Ther Targets 14:303-316
-
(2010)
Expert Opin Ther Targets
, vol.14
, pp. 303-316
-
-
Ye, F.1
Gao, Q.2
Cai, M.J.3
-
151
-
-
68049095262
-
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance
-
19584161 1:CAS:528:DC%2BD1MXosV2ltL8%3D 10.1158/1078-0432.CCR-08-3012
-
Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN (2009) MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15:4622-4629
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4622-4629
-
-
Yip, S.1
Miao, J.2
Cahill, D.P.3
Iafrate, A.J.4
Aldape, K.5
Nutt, C.L.6
Louis, D.N.7
|